The Medicare GLP-1 Bridge and Compounded Medications: What's Covered, What's Not

On July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched the BALANCE Model — colloquially called the "Medicare GLP-1 Bridge" — providing Medicare Part D beneficiaries access to GLP-1 medications for weight management at reduced copays. For the 65 million Americans on Medicare, this is the first time weight-loss medications have been covered under Part D.

But here's the question compounded GLP-1 patients are asking: does the Bridge cover compounded semaglutide or tirzepatide? The answer, for now, is no — and understanding why helps you evaluate your options.

What the BALANCE Model Covers

The Medicare GLP-1 Bridge covers FDA-approved anti-obesity medications prescribed for weight management in Medicare beneficiaries who meet clinical criteria. The covered medications include brand-name products with FDA approval for chronic weight management:

• Wegovy (semaglutide 2.4 mg)
• Zepbound (tirzepatide, at approved weight-management doses)
• Other FDA-approved anti-obesity medications meeting CMS criteria

Copay Structure

The BALANCE Model caps beneficiary cost-sharing at approximately $50 per month during the initial phase, with costs potentially varying by plan and formulary placement. This represents a dramatic reduction from the $1,000+ monthly retail cost that previously made these medications unaffordable for most Medicare beneficiaries.

Eligibility Requirements

To qualify, beneficiaries must meet clinical criteria that typically include a BMI threshold (generally ≥30, or ≥27 with weight-related comorbidities), prescriber documentation of medical necessity, and enrollment in a participating Medicare Part D plan. The specific criteria may vary by plan, but the clinical framework follows established obesity medicine guidelines.

Why Compounded Medications Are Not Covered

The BALANCE Model, like Medicare Part D generally, covers FDA-approved prescription drugs — not compounded medications. This exclusion is not specific to GLP-1s; it reflects a fundamental structural feature of Medicare drug coverage:

• FDA approval requirement: Part D formularies include drugs that have undergone the FDA's approval process, including clinical trials demonstrating safety and efficacy. Compounded medications, by definition, have not undergone this process.
• National Drug Code (NDC) system: Medicare Part D claims processing uses NDC codes to identify covered products. Compounded medications do not have NDC codes in the same way that commercial products do, making them difficult to process through the Part D claims system.
• Manufacturer rebates: Part D coverage economics depend partly on manufacturer rebates negotiated between drug makers and pharmacy benefit managers. Compounding pharmacies do not participate in this rebate structure.

Comparing the Economics

For Medicare beneficiaries, the coverage landscape now presents a genuine comparison:

• Brand-name through BALANCE Model: ~$50/month with Medicare Part D coverage. Requires FDA-approved product, clinical criteria met, and participating plan. No compounding quality variables — standardized, FDA-inspected manufacturing.
• Compounded through cash-pay: $149-400/month out-of-pocket. No Medicare coverage. Requires prescription from a licensed prescriber. Subject to compounding pharmacy quality variation.
• Brand-name without coverage: $1,000+/month retail. Manufacturer savings programs may reduce cost but have eligibility restrictions for Medicare beneficiaries (federal anti-kickback considerations limit manufacturer copay assistance for federally funded programs).

For beneficiaries who qualify for the BALANCE Model, the economic argument for compounded GLP-1s weakens significantly. At $50/month for a standardized, FDA-approved product, the cost advantage of compounding largely disappears. The remaining reasons to choose compounded — dose customization, format preference, or specific provider relationships — become the deciding factors rather than price.

What Beneficiaries Should Do

1. Check whether your Medicare Part D plan participates in the BALANCE Model (not all plans do, especially in the program's first year).
2. Discuss clinical eligibility with your prescriber — BMI criteria, comorbidity documentation, and any prior authorization requirements.
3. Compare your current compounded medication cost against the Bridge copay to determine which option is more economical for your situation.
4. If you qualify for the Bridge, your prescriber can write a new prescription for the brand-name product. You do not need to stop compounded medication before starting — but you should not use both simultaneously without medical supervision.

Providers Serving Medicare Beneficiaries